UBROGEPANT

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C29H26F3N5O3
Molecular Weight	549.5436
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CN=C3C[C@]4(CC3=C2)C(=O)NC5=NC=CC=C45)C(=O)N1CC(F)(F)F)C6=CC=CC=C6

InChI

InChIKey=DDOOFTLHJSMHLN-ZQHRPCGSSA-N

InChI=1S/C29H26F3N5O3/c1-16-20(17-6-3-2-4-7-17)11-22(26(39)37(16)15-29(30,31)32)35-25(38)19-10-18-12-28(13-23(18)34-14-19)21-8-5-9-33-24(21)36-27(28)40/h2-10,14,16,20,22H,11-13,15H2,1H3,(H,35,38)(H,33,36,40)/t16-,20-,22+,28+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C29H26F3N5O3
Molecular Weight	549.5436
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://adisinsight.springer.com/drugs/800036373 | https://www.allergan.com/news/news/thomson-reuters/allergan-announces-fda-acceptance-of-new-drug-appl | http://indexsmart.mirasmart.com/AAN2019/PDFfiles/AAN2019-001191.pdf

Ubrogepant, a small molecule drug, is being developed by Merck & Co for the treatment of migraine. The calcitonin gene-related peptide receptor (CGRP) antagonist is administered orally as a film coated tablet. Ubrogepant is a competitive antagonist with high affinity, potency, and selectivity for the human CGRP receptor. In the four clinical studies (ACHIEVE I, ACHIEVE II, UBR-MD-04 and 3110-105-002) ubrogepant demonstrated efficacy, safety and tolerability in the acute treatment of migraine among a broad patient population, including those who had an insufficient response to a triptan or those patients in whom triptans were contraindicated, as well as in patients who had moderate to severe CV risk profile.

Originator

Approval Year

C_max

Value	Dose	Analyte	Population
281.97 nM EXPERIMENT https://journals.sagepub.com/doi/pdf/10.1177/2515816320905082	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	UBROGEPANT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status:
274.25 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31628854/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	UBROGEPANT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1029.75 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31628854/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	UBROGEPANT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
1306.54 nM × h EXPERIMENT https://journals.sagepub.com/doi/pdf/10.1177/2515816320905082	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	UBROGEPANT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status:
1249.39 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31628854/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	UBROGEPANT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5127.06 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31628854/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	UBROGEPANT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
3.54 h EXPERIMENT https://journals.sagepub.com/doi/pdf/10.1177/2515816320905082	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	UBROGEPANT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status:
4.41 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31628854/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	UBROGEPANT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5.06 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31628854/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	UBROGEPANT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
25 mg multiple, oral Dose: 25 mg Route: oral Route: multiple Dose: 25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31742631/	unhealthy, 18-71 years n = 478 Health Status: unhealthy Condition: migraine Age Group: 18-71 years Sex: M+F Population Size: 478 Sources: https://pubmed.ncbi.nlm.nih.gov/31742631/	Other AEs: Upper respiratory tract infection, Nausea... Other AEs: Upper respiratory tract infection (1.3%) Nausea (2.9%) Nasopharyngitis (1%) Dizziness (2.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/31742631/
25 mg 1 times / day single, oral Dose: 25 mg, 1 times / day Route: oral Route: single Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31742631/	unhealthy, 18-71 years n = 478 Health Status: unhealthy Condition: migraine Age Group: 18-71 years Sex: M+F Population Size: 478 Sources: https://pubmed.ncbi.nlm.nih.gov/31742631/	Other AEs: Nausea, Dizziness... Other AEs: Nausea (2.5%) Dizziness (2.1%) Sources: https://pubmed.ncbi.nlm.nih.gov/31742631/
100 mg multiple, oral Recommended Dose: 100 mg Route: oral Route: multiple Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf	unhealthy, 18-75 years n = 485 Health Status: unhealthy Condition: migraine Age Group: 18-75 years Sex: M+F Population Size: 485 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf	Disc. AE: Nausea... Other AEs: Nausea, Somnolence... AEs leading to discontinuation/dose reduction: Nausea Other AEs: Nausea (4%) Somnolence (3%) Dry mouth (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf
50 mg multiple, oral Recommended Dose: 50 mg Route: oral Route: multiple Dose: 50 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31742631/	unhealthy, 18-75 years n = 488 Health Status: unhealthy Condition: migraine Age Group: 18-75 years Sex: M+F Population Size: 488 Sources: https://pubmed.ncbi.nlm.nih.gov/31742631/	Other AEs: Upper respiratory tract infection, Nausea... Other AEs: Upper respiratory tract infection (2.7%) Nausea (2.5%) Nasopharyngitis (2.3%) Dizziness (2%) Sources: https://pubmed.ncbi.nlm.nih.gov/31742631/
50 mg multiple, oral Recommended Dose: 50 mg Route: oral Route: multiple Dose: 50 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31742631/	unhealthy, 18-75 years n = 488 Health Status: unhealthy Condition: migraine Age Group: 18-75 years Sex: M+F Population Size: 488 Sources: https://pubmed.ncbi.nlm.nih.gov/31742631/	Other AEs: ALT increased, AST increased... Other AEs: ALT increased (0.4%) AST increased (0.2%) ALP increased (0.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/31742631/
50 mg multiple, oral Recommended Dose: 50 mg Route: oral Route: multiple Dose: 50 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf	unhealthy, 18-75 years n = 954 Health Status: unhealthy Condition: migraine Age Group: 18-75 years Sex: M+F Population Size: 954 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf	Other AEs: Nausea, Somnolence... Other AEs: Nausea (2%) Somnolence (2%) Dry mouth (< 1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf
50 mg 1 times / day single, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: single Dose: 50 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31742631/	unhealthy, 18-75 years n = 488 Health Status: unhealthy Condition: migraine Age Group: 18-75 years Sex: M+F Population Size: 488 Sources: https://pubmed.ncbi.nlm.nih.gov/31742631/	Other AEs: Nausea, Dizziness... Other AEs: Nausea (2%) Dizziness (1.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/31742631/
100 mg multiple, oral Recommended Dose: 100 mg Route: oral Route: multiple Dose: 100 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31913519/	unhealthy, average 42 years n = 409 Health Status: unhealthy Condition: migraine Age Group: average 42 years Sex: M+F Population Size: 409 Sources: https://pubmed.ncbi.nlm.nih.gov/31913519/	Disc. AE: Abnormal ECG, Extrasystoles... Other AEs: Nasopharyngitis, Upper respiratory tract infection... AEs leading to discontinuation/dose reduction: Abnormal ECG (0.2%) Extrasystoles (0.2%) Nausea (0.2%) Palpitations (0.2%) Pruritus (0.2%) ALT increased (0.2%) AST increased (0.2%) Other AEs: Nasopharyngitis (grade 1-2, 11.5%) Upper respiratory tract infection (grade 1-2, 10.8%) Sinusitis (grade 1-2, 6.4%) Urinary tract infection (grade 1-2, 6.4%) Influenza (grade 1-2, 6.1%) Nausea (grade 1-2, 4.6%) Bronchitis (grade 1-2, 4.4%) Blood creatine phosphokinase increased (grade 1-2, 3.9%) ALT increased (grade 1-2, 3.7%) AST increased (grade 1-2, 3.4%) Back pain (grade 1-2, 3.4%) Nephrolithiasis (grade 1-2, 3.2%) Dizziness (grade 1-2, 2.9%) Anxiety (grade 1-2, 2.7%) Cough (grade 1-2, 2.7%) Diarrhea (grade 1-2, 2.7%) Arthralgia (grade 1-2, 2.4%) Gastroenteritis viral (grade 1-2, 2.4%) Muscle strain (grade 1-2, 2.4%) Depression (grade 1-2, 1.2%) Migraine (grade 1-2, 1%) Abdominal pain (grade 1-2, 0.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/31913519/
50 mg multiple, oral Recommended Dose: 50 mg Route: oral Route: multiple Dose: 50 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31913519/	unhealthy, average 42 years n = 404 Health Status: unhealthy Condition: migraine Age Group: average 42 years Sex: M+F Population Size: 404 Sources: https://pubmed.ncbi.nlm.nih.gov/31913519/	Disc. AE: Nausea, Thrombocytopenia... Other AEs: Nasopharyngitis, Upper respiratory tract infection... AEs leading to discontinuation/dose reduction: Nausea (0.2%) Thrombocytopenia (0.2%) Urticaria (0.2%) Vomiting (0.2%) Other AEs: Nasopharyngitis (grade 1-2, 8.2%) Upper respiratory tract infection (grade 1-2, 11.6%) Sinusitis (grade 1-2, 6.9%) Urinary tract infection (grade 1-2, 5.4%) Influenza (grade 1-2, 4.2%) Nausea (grade 1-2, 4.7%) Bronchitis (grade 1-2, 3.2%) Blood creatine phosphokinase increased (grade 1-2, 2.5%) ALT increased (grade 1-2, 2.2%) AST increased (grade 1-2, 1.7%) Back pain (grade 1-2, 3.5%) Nephrolithiasis (grade 1-2, 1%) Dizziness (grade 1-2, 1.2%) Anxiety (grade 1-2, 1.5%) Cough (grade 1-2, 2%) Diarrhea (grade 1-2, 2.5%) Arthralgia (grade 1-2, 2.7%) Gastroenteritis viral (grade 1-2, 1.7%) Muscle strain (grade 1-2, 0.5%) Depression (grade 1-2, 3.2%) Migraine (grade 1-2, 1.5%) Abdominal pain (grade 1-2, 1%) Epididymitis (grade 1-2, 3.2%) Testicular pain (grade 1-2, 3.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/31913519/
400 mg 1 times / day single, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: single Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31628854/	healthy, mean age 29.2 years n = 76 Health Status: healthy Age Group: mean age 29.2 years Sex: M+F Population Size: 76 Sources: https://pubmed.ncbi.nlm.nih.gov/31628854/	Other AEs: Nausea, Diarrhea... Other AEs: Nausea (1.3%) Diarrhea (2.6%) Abdominal pain (1.3%) Vomiting (1.3%) Medical device site reaction (1.3%) Vessel puncture site pain (2.6%) Electrocardiogram QT prolonged (1.3%) AST increased (1.3%) Headache (2.6%) Insomnia (1.3%) Cough (1.3%) Oropharyngeal pain (1.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/31628854/
400 mg 1 times / day multiple, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31899602/	healthy, range 21–51 years n = 6 Health Status: healthy Age Group: range 21–51 years Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/31899602/	Other AEs: Headache, Nausea... Other AEs: Headache (grade 1-2, 16.7%) Nausea (grade 1-2, 16.7%) Abdominal discomfort (grade 1-2, 16.7%) Abdominal pain upper (grade 1-2, 16.7%) Application site irritation (grade 1-2, 16.7%) Herpes simplex (grade 1-2, 16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/31899602/

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587 inducer 781	inhibitor 1767	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2B6 810 CYP2C8 911 CYP2C19 1478 UGT1A1 204 P-gp 1461 BCRP 699 BSEP 402 MRP3 157 MRP4 204 OAT1 599 OAT3 642 OATP1B1 788 OATP1B3 706 OCT2 647	P-gp 1537 BCRP 561 OATP1B1 406 OATP1B3 350 OAT1 326 OAT3 339	CYP1A2 701 CYP2B6 547

Drug as perpetrator

Target	Modality	Activity
BCRP 773	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	no
BSEP 403	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	no
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	no
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	no
MRP3 207	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	no
MRP4 238	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	no
OAT1 603	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	no
OAT3 644	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	no
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	weak
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	weak
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	weak
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	weak
OATP1B1 803	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	weak
OATP1B3 715	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	weak
OCT2 648	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	weak
UGT1A1 254	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	weak

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=7 Page: 7.0	major	yes (co-administration study) Comment: Co-administration of ubrogepant with ketoconazole, a strong CYP3A4 inhibitor, resulted in a 9.7 fold increase in ubrogepant AUC0-inf and a 5.3-fold increase in ubrogepant Cmax Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=7 Page: 7.0
OAT3 339	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	no
OAT1 326	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	weak
OATP1B1 406	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	weak
OATP1B3 350	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	weak
BCRP 561	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	yes
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=9 Page: 9.0	yes	likely (co-administration study) Comment: Drug interaction with verapamil (a combined P-gp inhibitor and moderate CYP3A4 inhibitor) resulted in a 3.5-fold increase in exposure. This increase in exposure can be due to the combined P-gp/CYP3A4 inhibition and the relative contribution of P-gp inhibition needs to be segregated to provide dose adjustment recommendation with P-gp only inhibitors Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000ClinPharmR.pdf#page=9 Page: 9.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000PharmR.pdf#page=18 Page: 18.0

Sourcing

Vendor/Aggregator	ID	URL
CSNpharm	CSN22530	https://www.csnpharm.com/products/ubrogepant.html
Chem Scene	CS-0011109	http://www.chemscene.com/1374248-77-7.html
ChemFish Tokyo co.,ltd	68748835	http://www.chemfish.co.jp/index.php?id=4218&project=product
DC Chemicals	DC22151	http://www.dcchemicals.com/product_show-DC22151.html
Excenen	EX-A3049	https://www.excenen.com/searchresultlist.php?id=1374248-77-7
Hairui	UBCQ025	http://www.hairuichem.com/en/product/1374248-77-7.html
Lab Network	LN01302341	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01302341
MedChem Express	HY-12366	https://www.medchemexpress.com/Ubrogepant.html
MolPort	MolPort-044-181-514	https://www.molport.com/shop/molecule-link/MolPort-044-181-514
Synblock Inc	SB19741	http://www.synblock.com/product/1374248-77-7.html
THE BioTek	bt-242411	https://www.thebiotek.com/product/peptides/bt-242411
abcr GmbH	AB534370	http://www.abcr.com/shop/en/AB534370
eNovation Chemicals	D674147	https://www.enovationchem.com/ProductDetails.asp?ProductID=D674147

PubMed

Title	Date	PubMed
A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.	2016 Aug	27269043
CGRP as the target of new migraine therapies - successful translation from bench to clinic.	2018 Jun	29691490
Therapeutic novelties in migraine: new drugs, new hope?	2019 Apr 17	30995909
Advances in orally administered pharmacotherapy for the treatment of migraine.	2019 Feb	30475090

Patents

Sample Use Guides

In Vivo Use Guide

Migraine: ubrogepant 1 mg, 10 mg, 25 mg, 50 mg, 100 mg. Ubrogepant 100 mg was significantly superior to placebo for two-hour pain freedom but not for two-hour headache response.

Route of Administration: Oral

In Vitro Use Guide

The binding affinity for native (Ki=0.067 nM) and cloned human (Ki=0.070 nM) and rhesus (Ki=0.079 nM) receptors was similar for ubrogepant, with relatively lower affinities for CGRP receptors of other species (ranging from Ki=9.6 to 47 nM). Ubrogepant potently blocked human α-CGRP–stimulated cAMP response (IC50 of 0.08) and exhibited highly selective antagonist activity in relation to the CGRP receptor compared with other members of the human calcitonin receptor family.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 04:53:26 GMT 2023` Edited by `admin` on `Sat Dec 16 04:53:26 GMT 2023`
Record UNII	AD0O8X2QJR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

UBROGEPANT

Official Name

English

SPIRO(6H-CYCLOPENTA(B)PYRIDINE-6,3'-(3H)PYRROLO(2,3-B)PYRIDINE)-3-CARBOXAMIDE, 1',2',5,7-TETRAHYDRO-N-((3S,5S,6R)-6-METHYL-2-OXO-5-PHENYL-1-(2,2,2-TRIFLUOROETHYL)-3-PIPERIDINYL)-2'-OXO-, (3'S)-

Systematic Name

English

Ubrogepant [WHO-DD]

Common Name

English

UBROGEPANT [MI]

Common Name

English

UBROGEPANT ANHYDROUS

Common Name

English

UBRELVY

Brand Name

English

(3'S)-N-((3S,5S,6R)-6-METHYL-2-OXO-5-PHENYL-1-(2,2,2-TRIFLUOROETHYL)PIPERIDIN-3-YL)-2'-OXO-1',2',5,7-TETRAHYDROSPIRO(CYCLOPENTA(B)PYRIDINE-6,3'-PYRROLO(2,3-B)PYRIDINE)-3-CARBOXAMIDE

Systematic Name

English

UBROGEPANT [ORANGE BOOK]

Common Name

English

UBROGEPANT [USAN]

Common Name

English

ubrogepant [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C241